Research milestones, fundraising, and awareness from Violehealth.
KCNQ2 is one of the most common causes of neonatal genetic epilepsy. Here is what families and supporters should know.
April 10, 2026
Violehealth is preparing its first investigator-initiated grant cycle focused on the KCNQ2 PIP2-binding pathway.
February 15, 2026
A father turns an impossible diagnosis into a mission to fund gene therapy research for children with KCNQ2 mutations.
September 1, 2025
